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Oxygen Supply/Demand Approach to Reducing Infarct Size
Great strides have been made in the treatment of acute myocardial infarction (MI). Improved outcomes and reduced mortality are largely the result of opening the occluded infarct artery as soon as possible and by keeping it open. Early reperfusion consistently reduces myocardial infarct size in both experimental animal models and in patients.
Despite advances in stenting of the occluded coronary artery and shortening of the "doorto-balloon" time, 1 month mortality post infarction still hovers around 15% and post myocardial infarction heart failure remains problematic. Therefore, there is still a need to try to further reduce myocardial infarct size in 2013. Initial concepts focused on reducing myocardial infarct size by improving the imbalance between O 2 /nutrient supply and O 2 /nutrient demand of the heart (Table 1) . Improving O 2 supply by inducing early reperfusion with thrombolytic therapy, then angioplasty, and now stenting has been successful and dual antiplatelet therapy and possibly addition of anticoagulant therapy has further improved clinical outcomes, maintained vessel patency, and reduced stent thrombosis. Other techniques to improve O 2 /nutrient supply such as hyperoxemia and erythropoietin have shown benefit in some but not all studies. Antianginal agents that vasodilate the coronary arteries and may improve coronary flow such as nitrates and calcium blockers in general have failed to reduce myocardial infarct size in clinical trials.
While restoring O 2 supply reduces ischemic cardiac damage due to myocardial infarction, attempts at reducing myocardial infarct size by reducing O 2 demand have yielded mixed results.
Early clinical studies with beta blockers in the pre-reperfusion era were negative. However chronic beta blockers post MI were suggested to reduce fatal ventricular arrhythmias, reduce reinfarction and limit LV remodeling and post-MI heart failure and death. Some beta blockers combined with reperfusion were shown to reduce myocardial infarct size 1 and limit ize by improving the imbalance between O 2 /nutrient supply and O 2 /nutrient dem m mand nd n o of f f th th the e e he h heart Table 1 ). Improving O 2 supply by inducing early reperfusion with thrombolytic therapy, then an ngi gi giop op opla la last st sty, y, y a a and d n n no ow ow stenting has been successf f fu ul ul a a and dual antipl pl lat a a elet et t t t th he h rapy and possibly f f f f f f ad dd di diti t on of an nti tic co oa a agul ul ulan an nt t t th th the er era ap apy y ha ha has s f fu fur rthe er r i impr r ro ov ved d d c c cli lin n nic ca al l o ou outc tcom om mes s s, ma ma mai in inta tain in ined ed ed v v ves es sse sel l l pa pate te tenc nc ncy, y, y, a and nd nd r red educ uc ced ed s ste e ent nt th hr hrom om mbo bo bosi sis s. . O O Oth th ther r r t t tec ec echn hn niq iq que ue ues s s to to to i imp mp m ro rove ve ve O O O 2 / /n /nut ut tri ri r en en ent t su su sup pp ppl ly ly s suc uch h h a as as hyperoxemia a an an and d er er eryt yt ythr hr hrop opoi oi o et et e in n n h h hav av ve e sh sh show ow own n n be be bene ne nef f fit it t i in n so so some me me b b but ut ut not ot ot a a all ll l s s stu tu tudi di d es es es. . . A A Ant nt ntia ianginal f f f f microvascular damage, 2 and in TIMI IIb immediate intravenous metoprolol coupled with thrombolysis reduced recurrent chest pain and reinfarction compared to delayed beta blockade.
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There has been a lack of large contemporary studies testing the effect of beta blockers coupled with angioplasty/stenting to determine whether in this setting they further reduce ischemic necrosis. Some studies suggested that other drugs that reduce oxygen demand, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers are capable of reducing myocardial infarct size. 4, 5 However, again there is little data from large contemporary studies combining these agents with early reperfusion achieved by percutaneous coronary intervention to determine whether they are capable of further reducing infarct size. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers given chronically after myocardial infarction have been shown to reduce post-MI remodeling, heart failure, and for ACE-inhibitors, reduce mortality. 6 Another approach to reduce O 2 demand is by making the heart hypothermic. In experiments in our laboratory, this approach has consistently worked to reduce myocardial infarct size. 7 Hypothermia slows the reduction of myocardial ATP during ischemia and this appears to us to be a logical mechanism of action; however, recent studies suggest that hypothermia also may preserve certain signal transduction pathways including extracellular signal -regulated Kinase, which could be another mechanism of action. 8 Clinical studies with hypothermia in patients with acute myocardial infarction have shown variable results, largely due to technical difficulties, such as inability to cool the heart great enough and quick enough prior to reperfusion. In clinical studies of anterior wall myocardial infarction in which temperature is reduced to 35%°C prior to reperfusion there has been a positive signal for reduction in whether they are capable of further reducing infarct size. Angiotensin convertin ng g g en en nzy zy yme me me nhibitors and angiotensin receptor blockers given chronically after myocardial infarction have be een en en s s sho ho hown wn wn t t to o re re edu du duc ce post-MI remodeling, heart rt rt f fa ai ilure, and for AC A A E-E-in in inh hibitors, reduce m mor rt rtality. 6 An not ot the er r ap appr pr proa oa oach ch ch t to o re re red du duc ce ce O 2 d d de e eman n nd d d is b by y y m m maki ki k n ng g t t the he h h hea a art t h h hyp y ypot othe he her rm rmic i i . . I In n ex xpe pe peri ri rime me m nt nt ts s s i in in o our ur r l lab ab bor or rat ator ory, y, y t t thi hi his s s a ap app pr proa oa oach ch ch h h ha a as s c co con nsi is iste te ent nt ntly ly w w wo o orke ke ked d d t to to r r red ed du uc uce e e my my myo o ocar ar rdi di ial al nfarct size.
myocardial infarct size. Heat exchange catheters have been tried but may not be adequate to reduce rapid and sufficient cooling, in all patients. Recently, a cooling "ThermoSuit" (Life Recovery Systems Napa, CA), was developed that induces systemic cooling very rapidly, achieving core temperatures of ~33.0 degrees C within 5-12 minutes. 9 Such approaches are already being applied to cardiac arrest patients, in which therapy is begun in the field. This method of inducing hypothermia has yet to be applied to a myocardial infarct size reducing clinical trial. Other pharmacologic agents that have shown promise for reducing infarct size are adenosine infusions and ivabradine. Adenosine agonists and adenosine infusions can slow heart rate, vasodilate and in both some experimental and 2 large clinical trials showed reduction of anterior wall myocardial infarctions. Ivabradine, the If sodium channel blocker that slows heart rate without dropping blood pressure, appears promising in experimental models of infarct size reduction, but has not been tested clinically.
Mechanical Unloading for Reducing Infarct Size
Mechanical unloading is another approach that has been tried for reduction of myocardial oxygen demand and infarct size. While some experimental myocardial infarct size studies using intra-aortic balloon counterpulsation (IABP) showed reductions, in infarct size, 10 this technique, that primarily reduces afterload, was unsuccessful in reducing myocardial infarct size in humans or in reducing death from cardiogenic shock. 11, 12 The reason for the negative clinical trials is unclear, as discussed by Kapur et al. 13 Experimental studies with a catheter mounted axial flow pump (moving blood from left ventricle (LV) to aorta) that reduced preload, did reduce infarct size in experimental models.
14 R.W. Smalling et al. 14 subjected anesthetized dogs to 2 hours of left anterior descending coronary artery occlusion followed by 1 hour of reperfusion and compared the effect of a anterior wall myocardial infarctions. Ivabradine, the If sodium channel blocker t th ha hat t t sl low ow ows s s he he hear art ate without dropping blood pressure, appears promising in experimental models of infarct size e edu du uct ct ctio io ion, n, b b but ut u has as as n not been tested clinically.
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Me Me ech ch chan an a ic ical al al u u unl nlo o oad di ding ng g i is s s an anot ot othe he er r r ap ap appr pro oa oach ch ch t t tha ha at t t ha ha as be been en en t t tri ri ried ed d fo fo f r r r re re redu du d c c cti io ion n of of of m m myo yo yoc c card rd dia a al l oxygen deman an nd d d an an nd d d in in nfa fa farc c ct t t si si size ze e. . W W Whi h h le le le s s som om ome e e ex ex e pe pe peri ri ime me ent nt n al al al m m myo yo yoca card rd rdia ia ial l l in in infa fa farc rct t t si si size ze ze s s stu tu t dies using g g Hemopump transvalvular axial-flow LV assist device to intra-aortic balloon counterpulsation on LV unloading, coronary collateral blood flow and reduction of infarct size. The Hemopump device was placed through a laporatomy into the common iliac arteries and then it was advanced under fluoroscopic control across the aortic valve. Comparator animals received an intra-aortic balloon catheter placed by cutdown into the femoral artery and advanced to the descending aorta.
Hemopump animals had a maximum flow increase of 3-3. diastolic unloading compared to the intra-aortic balloon counterpulsation device; both techniques reduced myocardial infarct size greater than reperfusion alone.
Achour et al. 15 assessed LV unloading just prior to reperfusion in dogs subjected to 2 hours of left anterior descending coronary artery occlusion plus 4 hours of reperfusion. A left ventricular assist device, placed transvalvularly was activated just prior to reperfusion.
Myocardial infarct size was reduced in the LV assist device group and transmural regional myocardial blood flow was improved in this group compared to controls. End diastolic wall thickness at reperfusion returned to baseline with LV assist started pre-reperfusion. Another group, treated with LV assist activated after reperfusion did not show benefit. The authors concluded that LV unloading prior to reperfusion, but not after reperfusion decreased the extent of myocardial necrosis compared to reperfusion alone or LV unloading that occurs after reperfusion has occurred. This group suggested that a potential mechanism by which LV unloading prior to reperfusion reduced infarct size was by reducing the release of endothelin-1 and reducing calcium overload. 16 Another group of researchers 17 showed in a canine model that a catheter-mounted microaxial blood pump (Impella, Aachen, Germany) turned on during 60 min. of ischemia and 120 min. of reperfusion in sheep, significantly reduced infarct size compared to controls (67% to 18%). The pump produced 4.1 L/min. flow at full support.
The pump increased diastolic and mean arterial pressure, decreased LV end-diastolic pressure, and improved reperfusion blood flow. It had partial benefits when used during reperfusion only. Importantly, the micro-axial blood pump was observed to reduce myocardial oxygen consumption during ischemia and reperfusion and the reduction in O 2 consumption correlated with the decrease in myocardial infarct size (r=0.9).
concluded that LV unloading prior to reperfusion, but not after reperfusion decrea ea ase e ed d th th he e e ex ex exte te t n nt of myocardial necrosis compared to reperfusion alone or LV unloading that occurs after e epe pe perf rf rfu us usio io ion n n ha ha h s oc oc occ cu curred. This group suggested d d t t tha ha at a potential me me m ch han an ani is ism by which LV u unlo o oad a ing prio or r t to t rep eper erfu fu fusi si sion on on r red ed duc uc uced ed d i in nfar rct t size e e w w was s s b b by y r r redu du d ci cin ng g t the he he r rel elea ea as se se o of f f en n ndo do doth h hel e elin n in-1 1 1 an nd d d re re edu du d ci cing ng ng c cal alci cium um u ov ve verl r oa oa ad. d. 16 16 Anot the he her r r gr gr grou ou oup p p of o o r res es e ea ea e rc rc che he h rs rs rs 17 17 17 s s sho ho howe we wed d d in in n a a a c c can anin in ine e e mo mo mode de del l l th h hat at at a a a c c cat at athe he h te te ter-r-r mo mo moun un u ted micro---Other studies by other researchers have suggested that unloading the LV with an LV assist device reduces infarct size. 18, 19 One study suggested an added benefit of unloading the LV plus administering an ultra short acting beta blocker. 19 Clinical studies using these newer LV support devices for infarct size reduction are not available, but these devices have shown promise in stabilizing patients with cardiogenic shock.
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The Present Study
Kapur et al. 13 provide an intriguing study in this issue of Circulation, suggesting that a circulatory support device that reduces left ventricular preload with a left atrial to femoral artery pumping approach decreased LV wall stress and LV stroke work after reperfusion and limited infarct size even when treated animals received an additional 30 minutes of ischemia, during which left ventricular unloading was activated. The benefit of this type of unloading may be secondary to reduction in oxygen demand, but also intriguing was their observation that phosphorylation of Reperfusion Injury Salvage Kinase pathway proteins (pERK and pAkt) was increased in samples of the left ventricle obtained from the non-infarct zone (but not the infarct zone). Since this non-infarcted tissue was neither ischemic nor reperfused, the significance of this finding remains to be determined.
Their experimental design was unusual. Anesthetized pigs in the control group were subjected to 120 minutes of left anterior descending balloon coronary artery occlusion, followed by 120 minutes of reperfusion. In the treated group, mechanical unloading (percutaneous left atrial to femoral artery bypassing which utilizes a centrifugal flow pump that achieved 3.2 liters/minute flow) was initiated after 120 minutes of coronary artery occlusion and the coronary occlusion was then extended for an additional 30 minutes with the device on, followed by 120 minutes of coronary reperfusion with the mechanical support device working. Despite the fact nfarct size even when treated animals received an additional 30 minutes d of isch hem e emia ia i , du du duri ri ring ng ng which left ventricular unloading was activated. The benefit of this type of unloading may be e eco co ond nd nda ar ary y y to to to r red duc uc ucti tion in oxygen demand, but a a als ls lso intriguing wa as s s thei ei ir r r o ob observation that ph ho os osphorylatio ion n of f R Re e epe er erf fu fusi si sio on on I Inj nj nju ur ury y y S S Salv vag ag age K Ki in n nase e e p p pat athw hw hway ay pr ro rote tein in ins s (p (p pER ER ERK K a an and d d pA pA p kt kt kt) ) wa wa was n ncr cr crea ea ase se s d d in in n s sam am mpl pl les es o o of f th the e le le eft ft v v ven en ent tr tric ic cle le e o o obt bt btai i ine ne n d d d fr fr rom om m t t the he he non on on-i -i inf nf far ar arct ct t z zon on o e e e ( ( (bu bu b t t no no not t th th he in infa fa arc c ct t zone). Since e th th this is i n n non on o -i -inf n n ar ar rct ct cted ed e t t tis is ssu su ue e wa wa was s s ne ne neit it i h h her er er i i isc sc che hemi mi mic c c no no nor r r re re r pe pe perf rf rfus us used ed ed, , , th the e e si si sign gn gnif if fic i ance of I suspect additional experimental and clinical trials will be needed before they are convinced.
The authors point out several limitations of their study. Perhaps the biggest concern is the small n values. An n of 4 in each group is small for this type of study and when the n value is that small a single outlier can have major impact. Future studies in which the n values are considerably larger are needed. There should be some type of risk zone assessment. Although the authors showed that there was no difference in coronary length or left ventricular mass distal to the occlusion site, a more traditional anatomic risk zone that assesses the mass of the left ventricle that was ischemic is preferable. Strengths of the study include the unique experimental design and findings regarding infarct size, the success of their mechanical unloading device that reduced LV end-diastolic pressure, provided 3.2 liters/minute flow, decreased LV stroke work, circumferential LV strain, and LV wall stress during reperfusion while maintaining systemic ventricle salvages more myocardium than not delaying door to balloon time wit tho ho out ut ut u unl nl nloa oa oadi di ding ng he left ventricle. Whether interventional cardiologists would be willing to buy into delaying do oor or or t t to o o ba ba ball ll lloo oo on ti ti tim me me in order to unload the left ve ve vent nt tr ricle prior to r re e eperf rf fus us usio i n remains to be seen. su u usp s ect addi iti tio on na a al e ex x xpe er erim im imen en enta tal l an an and d cl cli inica al a tria al ls wil ll ll b be e ne ne eed eded ed b bef ef fo o ore e e th th hey ey y a are re e c con on o vi v v n nc nced ed ed.
Th The e e a au auth thor or ors s po po oin n nt t ou out t t se se eve ve vera ra ral l li li imi mi mita ta tat ti tion on ns s s o of of t the e eir r st st stu ud udy. y. y. P Pe Perh rh rhap ap ps th th t e e bi bi bigg gg gge es est t t co onc nc cer ern n n is s he small n va va alu lu lues es s. . An An An n n n of f f 4 4 4 in in e e eac ac a h h h gr gr rou ou oup p p is is is s sma ma mall ll l f f for or t t thi hi his s s ty ty type pe pe o of f f st st stud ud udy y y an an and d wh wh when en en t t the h h n value arterial pressure, and measuring both anatomic myocardial infarct size as well as enzymatic estimates of necrosis during reperfusion. 
